GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectar Biosciences Inc (NAS:CLRB) » Definitions » Insider Ownership

Cellectar Biosciences (Cellectar Biosciences) Insider Ownership : 7.05 % (As of Apr. 27, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Cellectar Biosciences Insider Ownership?

Insider ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Cellectar Biosciences's insider ownership is 7.05%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Cellectar Biosciences's Institutional Ownership is 6.84%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Cellectar Biosciences's Float Percentage Of Total Shares Outstanding is 99.89%.


Cellectar Biosciences Insider Ownership Historical Data

The historical data trend for Cellectar Biosciences's Insider Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Insider Ownership Chart

Cellectar Biosciences Historical Data

The historical data trend for Cellectar Biosciences can be seen below:

2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31 2024-01-31 2024-02-29 2024-03-31
Insider Ownership 6.60 6.60 6.60 6.60 6.60 6.60 7.05 7.05 7.05 7.05

Cellectar Biosciences Insider Ownership Calculation

The percentage of shares that are owned by company insiders relative to the total shares outstanding.


Cellectar Biosciences (Cellectar Biosciences) Business Description

Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. Its lead PDC therapeutic, iopofosine is a small-molecule PDC designed to provide targeted delivery of iodine-131 directly to cancer cells, while limiting exposure to healthy cells.
Executives
Andrei Shustov officer: Senior Vice President, Medical 7 PARKLAND DRIVE, MILFORD NJ 08848
Darrell Shane Lea officer: Chief Commercial Officer 7 PARKLAND DRIVE, MILFORD NJ 08848
Chad J Kolean officer: Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC., 3301 AGRICULTURE DRIVE, MADISON WI 53716
Douglas J Swirsky director C/O REXAHN PHARMACEUTICALS, INC., 15245 SHADY GROVE ROAD SUITE 455, ROCKVILLE MD 20850
Frederick W Driscoll director
Asher Chanan-khan director C/O CELLECTAR BISCIENCES, INC., 100 CAMPUS DRIVE NJ 07932
James V Caruso director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC., 8383 GREENWAY BLVD STE 600, MIDDLETON WI 53562
Dov Elefant officer: Chief Financial Officer EPICEPT CORPORATION, 270 SYLVAN AVENUE, ENGLEWOOD CLIFFS NJ 07632
Jarrod Longcor officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE, COLT NECK NJ 07722
John Neis director 505 S. ROSA ROAD, SUITE 201, MADISON WI 53719
Stefan Loren director 3226 AVENIDA DE SUENO, CARLSBAD CA 92009
Stephen A Hill director 50 AVENUE GENERAL DE GAULLE, BRUXELLES C9 9999999999
Igor D Grachev officer: Chief Medical Officer 15 REID LANE, MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD, MALVERN PA 19355